Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer

A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

RATIONALE: Drugs used in chemotherapy, such as topotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Topotecan and cisplatin may make tumor cells more sensitive to radiation therapy. Giving topotecan and cisplatin together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when given together with cisplatin and radiation therapy in treating patients with advanced cervical cancer.

OBJECTIVES:

• Determine the maximum tolerated dose of topotecan when administered with cisplatin in patients with advanced cervical cancer.
• Identify any unique toxicities associated with administering radiotherapy along with adjuvant cisplatin and topotecan in patients with cervical cancer.
• Determine the feasibility of administering continuous infusion topotecan chemotherapy together with radiation therapy.
• Assess the quality of life of patients treated with this regimen.

OUTLINE: This is a dose-escalation study of topotecan.

Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Quality of life is assessed at baseline and at 4 and 14 weeks after completion of study treatment.

After completion of study treatment, patients are followed periodically.

Inclusion Criteria:

• Histologically confirmed cervical carcinoma

  • Deemed not curable by surgery or radiotherapy alone

  • The following stages are eligible:

    • Stage IIB

    • Stage IIIA or IIIB

    • Stage IVA

    • Stage IB or IIA with ≥ 1 of the following risk factors:

      • Primary tumor ≥ 6 cm
      • Positive pelvic and/or para-aortic lymph nodes (resected or unresected)
      • Positive surgical margins
      • Depth of invasion > 50% and positive capillary-lymphatic space involvement

• The following histologic subtypes are eligible:

  • Squamous
  • Adenosquamous
  • Adenocarcinoma

• No recurrent cervical cancer

• Gynecologic Oncology Group (GOG) performance status 0, 1, or 2

• White blood cells (WBC) ≥ 3,000/mm^3

• Platelet count ≥ 100,000/mm^3

• Granulocyte count ≥ 1,500/mm^3

• Creatinine ≤ 2.0 mg/dL

• Bilirubin ≤ 1.5 times institutional normal

• Serum glutamic oxaloacetic transaminase (SGOT) and alkaline phosphatase ≤ 3 times institutional normal

• No other prior or concurrent malignancies other than skin (excluding melanoma)

• No septicemia, severe infection, gastrointestinal bleeding, or intestinal obstruction

• No anatomic abnormalities (e.g., pelvic kidney or renal transplant) requiring modification of radiation fields

• Fertile patients must use effective contraception

• Negative pregnancy test

• Patients with evidence of abnormal cardiac conduction (e.g., bundle branch block, heart block) are eligible if disease is stable for the past 6 months

• Recovered from recent surgery

Exclusion Criteria:

• Prior pelvic radiation
• Pregnant or nursing
• History of thrombus
• History of unstable angina or myocardial infarction within the past 6 months